Overviews and highlights from expert Neurologists and an MS Nurse Practitioner 

 

Hear the latest updates from ECTRIMS 2025 and the impact on clinical practice for Neurologists in Australia. 

PBS Information:  Authority Required (STREAMLINED). For use in patients with relapsing-remitting multiple sclerosis who meet certain criteria. Refer to PBS Schedule for full Authority Required information.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) to delay the progression of physical disability and reduce the frequency of relapse.1

Please review full Product Information before prescribing. Very common adverse effects (≥10%) include injection related reaction, nasopharyngitis, injection site reaction and urinary tract infection.1

For more detailed safety information, refer to the Product Information.

This content is intended for Australian healthcare professions and is promotional.

 

Tags

  • Neurology